Biomarker ID | 869 |
PMID | 22355332 |
Year | 2012 |
Biomarker | Beta-2-gylcoprotien 1 + Somatomedin- B |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Serum |
Subjects | Humans |
Regulation | Upregulated: [Beta-2-gylcoprotien 1 (1.2 fold)+ Somatomedin- B (1.1 fold)] |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | BPH Vs Non Progressing Prostate Cancer |
Type of Biomarker | Diagnostic |
Cohort | Samples were collected from 4 groups with 5 samples each:benign prostatic hyperplasia (BPH); ii) localised cancer with no evidence of progression, (non-progressing) (iii) localised cancer with evidence of biochemical progression, (progressin), and (iv) bone metastasis at presentation (metastatic). |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p ≤0.01 |
Method Used | 4-plex iTRAQ |
Clinical | No |
Remarks | represents biomarkers assessed individualy, + represents biomarkers assessed as a pair or panel |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | APOH, VTN |